Market Overview

UPDATE: JP Morgan Downgrades Affymetrix to Underweight

Related AFFX
Looking For A Growth Stock? Why It Is Time To Focus On Affymetrix - Tale Of The Tape
Affymetrix, BioDiscovery Launch Cancer Research Software - Analyst Blog
Related AFFX
Affymetrix (AFFX) Stock: Moving Average Crossover Alert - Tale of the Tape
Can Medtronic (MDT) Surprise this Earnings Season? - Analyst Blog

JP Morgan lowered its rating on Affymetrix (NASDAQ: AFFX) from Neutral to Underweight on macro risk.

JP Morgan said, "We are lowering our rating on AFFX from Neutral to Underweight on the poor outlook for arrays in academic/research, and limited flexibility for capital deployment following the eBiosciences acquisition. ... With increasing competition in arrays from Illumina and Agilent (Roche even felt the need to exit arrays recently), as well as sequencing and other platforms (desktop sequencers, nanofluidics platforms, etc.), we see little to stabilize the array business, particularly against the backdrop of a challenging U.S. and EU funding environment."

Affymetrix closed at $4.41 on Tuesday.

Posted-In: JP MorganAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (AFFX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters